Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The prediction for Rigel Pharmaceutical Inc. disappointed with a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | - | - | - | - |
| iShares Core DAX® | -1,59 % | 5,03 % | 6,33 % | 64,06 % |
| iShares Nasdaq 100 | -4,15 % | -0,13 % | 25,73 % | 86,92 % |
| iShares Nikkei 225® | -6,30 % | 0,53 % | 41,38 % | 77,87 % |
| iShares S&P 500 | -3,23 % | 0,47 % | 20,45 % | 68,19 % |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)